Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

TLX

Telix Pharmaceuticals Ltd. ADR

Dec 12 • 04:00PM ET

15.60

Dollar change -0.17
Percentage change -1.08	%

Healthcare • Biotechnology • Australia • NASD

Peers: LLY MRK JNJ PFE BMY AMGN REGN VRTX BMRN BIIB

Scroll to Statements

Index	-	P/E	160.82	EPS (ttm)	0.10	Insider Own	-	Shs Outstand	334.13M	Perf Week	-2.50%
Market Cap	5.22B	Forward P/E	86.48	EPS next Y	0.18	Insider Trans	-	Shs Float	-	Perf Month	-
Income	32.26M	PEG	-	EPS next Q	-	Inst Own	-	Short Float	-	Perf Quarter	-
Sales	423.35M	P/S	12.33	EPS this Y	64.69%	Inst Trans	62.83%	Short Ratio	0.39	Perf Half Y	-
Book/sh	0.81	P/B	19.33	EPS next Y	31.61%	ROA	9.15%	Short Interest	0.01M	Perf Year	-
Cash/sh	0.24	P/C	65.79	EPS next 5Y	-	ROE	20.14%	52W Range	14.44 - 19.99	Perf YTD	2.97%
Dividend Est.	-	P/FCF	234.89	EPS past 5Y	-	ROI	11.44%	52W High	-21.96%	Beta	-
Dividend TTM	-	Quick Ratio	0.87	Sales past 5Y	743.28%	Gross Margin	71.74%	52W Low	8.03%	ATR (14)	1.16
Dividend Ex-Date	Apr 18, 2006	Current Ratio	0.99	EPS Y/Y TTM	198.21%	Oper. Margin	10.05%	RSI (14)	-	Volatility	8.13% -
Employees	-	Debt/Eq	0.05	Sales Y/Y TTM	76.17%	Profit Margin	7.62%	Recom	1.78	Target Price	17.23
Option/Short	No / Yes	LT Debt/Eq	0.05	EPS Q/Q	-	Payout	-	Rel Volume	0.38	Prev Close	15.77
Sales Surprise	3.65%	EPS Surprise	-33.22%	Sales Q/Q	-	Earnings	Aug 22 AMC	Avg Volume	22.78K	Price	15.60
SMA20	-0.17%	SMA50	-0.17%	SMA200	-0.17%	Trades		Volume	8,592	Change	-1.08%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-15-24	Initiated	UBS	Buy	$21

Nov-28-24 04:22AM	First Patient Dosed in Phase III ZIRCON-CP Trial of TLX250-CDx for Kidney Cancer Imaging in Chinese Patients (PR Newswire)
Nov-18-24 06:20PM	Telix to Add FAP-Targeting Candidates to Theranostic Pipeline (GlobeNewswire)
Nov-13-24 04:28PM	Telix ADSs Commence Trading on Nasdaq (GlobeNewswire)

Telix Pharmaceuticals Ltd. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TLX

Telix Pharmaceuticals Ltd. ADR

Upgrade your FINVIZ experience